Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy - Full Text View

Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy

This study has been terminated.
( This study was stopped because of an inadequate rate of enrollment. )

Sponsored by:	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Information provided by:	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ClinicalTrials.gov Identifier:	NCT00083434

Purpose

The purpose of this study is to examine the effectiveness of epoetin alfa in treating anemia in patients who have cancer or who no longer have any signs of the cancer, but remain anemic as a result of their treatment.

Condition	Intervention	Phase
Anemia Cancer	Drug: Epoetin alfa	Phase III

MedlinePlus related topics:

Anemia Cancer

ChemIDplus related topics:

Epoetin alfa Erythropoietin

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Efficacy Study

Further study details as provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:

Study Completion Date:

December 2004

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

18 years of age or older
Body weight >/= 99lbs
ECOG 0-2
Anemia results from cancer, chemotherapy, radiotherapy or an association with hormonal therapy or immunotherapy
Screening hemoglobin level of </= 11.0 g/dL for men or </= 10.0 for women

Exclusion Criteria:

History of or concurrent second malignancy
Evidence of primary or metastatic malignancy involving the Central Nervous System

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00083434

Locations


United States, California
	Shapiro, Stafford & Yee
	Arcadia, California, United States, 91007
	California Cancer Center
	Fresno, California, United States, 93720
	Advanced Urology Medical Center
	Anaheim, California, United States, 92801

United States, Florida
	Tukoi Research
	North Miami, Florida, United States, 33161

United States, North Carolina
	Hanover Medical Specialists, PA
	Wilmington, North Carolina, United States, 28401

United States, Washington
	Madigan Army Medical Center Urology Services
	Tacoma, Washington, United States, 98431-5000

Sponsors and Collaborators

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

More Information

FDA Approved Product labeling, refer to the following link:http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ This link exits the ClinicalTrials.gov site

This link exits the ClinicalTrials.gov site

Additional information is provided at the following link:http://dailymed.nlm.nih.gov/dailymed/about.cfm This link exits the ClinicalTrials.gov site

For FDA Safety Alerts and Recalls refer to the following link:www.fda.gov/MEDWATCH/safety.htm This link exits the ClinicalTrials.gov site

Study ID Numbers:	EPO-CAN-303
First Received:	May 24, 2004
Last Updated:	June 29, 2007
ClinicalTrials.gov Identifier:	NCT00083434
Health Authority:	United States: Food and Drug Administration

Keywords provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:

Anemia

Cancer

Study placed in the following topic categories:

Epoetin Alfa

Hematologic Diseases

Anemia

Additional relevant MeSH terms:

Hematinics

Therapeutic Uses

Hematologic Agents

Pharmacologic Actions

ClinicalTrials.gov processed this record on August 21, 2008